What is 89Zr-CD147 used for?

89Zr-CD147 is indicated for Non-small cell lung cancer, Breast cancer.

Who makes 89Zr-CD147?

89Zr-CD147 is developed by Sinotau Pharmaceutical Group.

What are the side effects of 89Zr-CD147?

Common side effects include Fatigue, Nausea, Vomiting.

Last reviewed 2026-04-23 · How we verify

89Zr-CD147

Sinotau Pharmaceutical Group · Phase 1 active Small molecule

Targeting CD147

Targeting CD147 Used for Non-small cell lung cancer, Breast cancer.

At a glance

Generic name	89Zr-CD147
Sponsor	Sinotau Pharmaceutical Group
Drug class	Radioligand therapy
Target	CD147
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 1

Mechanism of action

CD147 is a transmembrane glycoprotein involved in tumor cell proliferation, invasion, and metastasis. Targeting CD147 has been shown to inhibit tumor growth and angiogenesis.

Approved indications

Non-small cell lung cancer
Breast cancer

Common side effects

Fatigue
Nausea
Vomiting

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

89Zr-CD147 CI brief — competitive landscape report
89Zr-CD147 updates RSS · CI watch RSS
Sinotau Pharmaceutical Group portfolio CI